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One significant intraoperative outcome of concern to anesthesiologists and orthopedic surgeons is controlling the 
amount of blood loss both intraoperatively and postoperatively.  The use of the antifibrinolytic, tranexamic acid 
(TXA), is an innovative strategy that has been shown to decrease postoperative bleeding as well as decrease the need 
for blood transfusions.  Currently, there are multiple intravenous tranexamic acid dose regimens that are being 
employed for orthopedic surgeries. In this study, the aim was to evaluate the effectiveness of a 2 dose regimen (1000 
mg within 30 minutes pre-op and 1000 mg 4-6 hrs post-op) compared to a single 1000 mg preoperative IVPB dose.  
This study was a retrospective cohort conducted on patients undergoing total hip arthroplasty (THA), total knee 
arthroplasty (TKA), and total shoulder arthroplasty (TSA).  Both TXA regimens resulted in similar transfusion rates 
and adverse event rates with no significant difference as determined by statistical analysis.  Our results indicate that a 
single preoperative IVPB 1000 mg dose of TXA is a cost effective way to prevent blood loss and postoperative 
complications without increasing adverse events. 
 
 140 bed rural community hospital    
 All patients that underwent total knee arthroplasty, total hip arthroplasty, and total shoulder arthroplasty were included 
in the study regardless of past medical history and comorbidities.   
 Patients undergoing partial knee arthroplasties and revisions were excluded. 
  For a 10-month period, the hospital employed a 2 dose tranexamic acid protocol (1000 mg IVPB pre-op as defined 
above and 1000 mg 4-6 hours post-op) which included 366 patients (112 patients having THA, 238 having TKA, and 
16 having TSA) and was labeled as Group I.   
 Following this period, the hospital employed a single dose tranexamic acid protocol (1000 mg preoperative dose 10 
minutes prior to incision) which included 232 patients (75 patients having THA, 136 having TKA, and 21 having 
TSA) and was labeled as Group II.  .   
 Data from Groups I and II were both collected in a retrospective manner using chart review.  
 Venous thromboembolism prophylaxis regimens consisted of either aspirin 325 mg BID for one month total, 
rivaroxaban 10 mg QD based on procedure TKA for 14 days and THA for 31 days, or warfarin which was dose 
adjusted based on a goal INR range of 1.8-2.5 for a total duration of 21 days. 
 The VTE prophylaxis for Group I consisted of 241 (66%) patients who received aspirin 325 mg BID, 69 (19%) who 
received warfarin, 51 (14%) who received rivaroxaban, and 5 (1%) which did not receive VTE prophylaxis (all TSA 
patients) as it was the clinical judgment of the orthopedic surgeon that VTE prophylaxis was not necessary.   
 The VTE prophylaxis for Group II consisted of 212 (91%) patients who received aspirin 325 mg BID, 10 (4%) who 
received warfarin, 5 (2%) who received rivaroxaban, 3 (1%) who received dabigatran, and 2 (1%) which did not 
receive VTE prophylaxis as it was the clinical judgment of the orthopedic surgeon that VTE prophylaxis was not 
necessary. 
 Statistical analysis was conducted using the chi squared test (a parametric analysis method) to compare transfusion 
rates and adverse events between Groups I and II. 
 
 Transfusion rates: Group II  (7 out of 232 patients transfused, 3.02%) 
compared to Group I (18 out of 366 patients transfused, 4.92%).   
• No significant difference between Group I and II as determined using the 
chi squared test (P value=0.27). 
• There were no cases of postoperative hematoma, wound bleeding or 
dehiscence in either group.  
 Adverse events: Group II (5 out of 232 patients, 2.15%) compared with  
Group I (9 out of 366 patients, 2.46%). 
• No significant difference between Group I and II as determinded  
using the chi squared test (P value=0.81). 
• Group II (1 PE, 0.43%) had a reduction in the number of thromboembolic 
events as compared to Group I (3 PE, 0.82% and 1 Stroke, 0.27%). 
Description Group I Group II 
Total Procedures 
  
Total Transfusions 
366 
  
18 (4.92%) 
  
232 
  
7 (3.02%) 
  
Table 1.  Tranexamic Acid Transfusions 
Description Group I 
 
Group II 
Total Procedures 
  
Total Events 
  
PE 
  
Stroke 
  
Transfer to Tele 
366 
  
9 (2.46%) 
  
3 (0.82%) 
  
1 (0.27%) 
  
4 (1.09%) 
232 
  
5 (2.15%) 
  
1 (0.43%) 
  
0  
  
1 (0.43%) 
Table 2.  Tranexamic Acid Adverse Events  
 The study was conducted in order to compare a flat fixed 2 dose regimen (1000 mg IVPB within 30 min pre-op and 1000 mg post op 4-6 
hrs)  to a flat fixed single dose regimen (1 pre-operative dose of 1000 mg). 
 First study to analyze the effects of tranexamic acid with the administration of a flat fixed 1000 mg dose regardless of comorbidities. 
 Previous studies analyzing the efficacy of tranexamic acid have used a weight based dosing regimen 
 
 
 
 
 
 
 
 
 
 
 Limitations of study 
• 4 different regimens of venous thromboembolic prophylaxis being employed by the orthopedic surgeons. 
• Gillette et al., a retrospective study consisting of 2046 patients which analyzed the use of aspirin, low molecular weight heparin, 
and warfarin for VTE prophylaxis in patients that had received tranexamic acid and undergone THA and TKA 
• Result: There was no difference in the rates of deep vein thrombosis and pulmonary embolism between the different regimens of 
VTE prophylaxis. 
• TXA groups were compared from different times of the year resulting in a different sample size for each group 
• Ideally sample size from each group would have been similar 
• Chi squared test does not rely on similar sample size 
• Orthopedic surgeons techniques creating variability 
 
 Advantages of study 
• Sequencing of TXA regimens allowed us to effectively compare regimens 
• Patient base demographics similar 
• Flat fixed regimens reduced calculation mistakes thus reducing pharmacodynamics variability 
• Patients with a past medical history of thrombolytic complications or other risk factors were not excluded 
 Both of the intravenous regimens that we compared in our study reduced the number of transfusions needed 
compared to previous studies without an increase in occurrence of adverse events. 
 Our results suggest that a single preoperative intravenous dose of tranexamic acid was just as effective as a two dose 
regimen. 
• The percentage of allogeneic transfusions needed for Group II was actually less than that of Group I but it was 
not significantly different.   
• The percentage of adverse events in Group II was less than that of Group I but there was not a significant 
difference.  
 Our results indicate that a single preoperative IVPB flat fixed dose of tranexamic acid is a cost effective way to 
prevent blood loss and postoperative complications without increasing adverse events.  
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